S
Scott Christopher Malcolm
Researcher at Sunovion
Publications - 22
Citations - 159
Scott Christopher Malcolm is an academic researcher from Sunovion. The author has contributed to research in topics: Reuptake inhibitor & Reuptake. The author has an hindex of 9, co-authored 22 publications receiving 152 citations. Previous affiliations of Scott Christopher Malcolm include University of Delaware.
Papers
More filters
Patent
Cycloalkylamines as monoamine reuptake inhibitors
Liming Shao,Fengjiang Wang,Scott Christopher Malcolm,Michael C. Hewitt,Larry R. Bush,Jianguo Ma,Mark A. Varney,Una Campbell,Sharon Rae Engel,Larry W. Hardy,Patrick Koch,John Emmerson Campbell +11 more
TL;DR: The cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis were discussed in this paper.
Patent
Tetralone-based monoamine reuptake inhibitors
Liming Shao,Fengjiang Wang,Scott Christopher Malcolm,Michael C. Hewitt,Larry R. Bush,Mark A. Varney,Una Campbell,Sharon Rae Engel,Larry W. Hardy,Patrick Koch,Jianguo Ma +10 more
TL;DR: The tetralone based amines and their use in the treatment of central nervous system disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease, are discussed in this paper.
Journal ArticleDOI
Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.
Liming Shao,Michael C. Hewitt,Scott Christopher Malcolm,Fengjiang Wang,Jianguo Ma,Una Campbell,Nancy A. Spicer,Sharon Rae Engel,Larry W. Hardy,Zhi-Dong Jiang,Rudy Schreiber,Kerry L. Spear,Mark A. Varney +12 more
TL;DR: The present work expands the chemical space known to offer potent inhibition of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) and discloses novel bicyclic octahydrocyclopenta-1H-isoindole scaffolds as potent triple reuptake inhibitors (TRIs) for the potential treatment of depression.
Journal ArticleDOI
Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
Liming Shao,Fengjiang Wang,Scott Christopher Malcolm,Jianguo Ma,Michael C. Hewitt,Una Campbell,Larry R. Bush,Nancy A. Spicer,Sharon Rae Engel,Lakshmi D. Saraswat,Larry W. Hardy,Patrick Koch,R. Schreiber,Kerry L. Spear,Mark A. Varney +14 more
TL;DR: A series of novel chiral amines that potently inhibit the in vitro reuptake of serotonin, norepinephrine and dopamine (triple reuptakes inhibitors) and were active in vivo in a mouse model predictive of antidepressant like activity are described.
Journal ArticleDOI
Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.
Liming Shao,Michael C. Hewitt,Fengjiang Wang,Scott Christopher Malcolm,Jianguo Ma,John Emmerson Campbell,Una Campbell,Sharon Rae Engel,Nancy A. Spicer,Larry W. Hardy,Rudy Schreiber,Kerry L. Spear,Mark A. Varney +12 more
TL;DR: In this paper, a chiral cyclohexylaryl amines with potent reuptake inhibition against the serotonin, norepinephrine and dopamine transporters and activity at 10 and 30 mpk PO in the mouse tail suspension test was developed.